Lurasidone information

Lurasidone
Clinical data
Pronunciation	/ljʊəˈræsɪˌdoʊn/
Trade names	Latuda, others
Other names	SM-13496
AHFS/Drugs.com	Monograph
MedlinePlus	a611016
License data	US DailyMed: Lurasidone;
Pregnancy; category	AU: B1; ;
Routes of; administration	By mouth
Drug class	Atypical antipsychotic
ATC code	N05AE05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	9–19% (oral)
Protein binding	~99%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	18–40 hours
Excretion	Faecal (67–80%),; renal (9–19%)
Identifiers
	IUPAC name (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione;
CAS Number	367514-87-2;
PubChem CID	213046;
IUPHAR/BPS	7461;
DrugBank	DB08815;
ChemSpider	184739;
UNII	22IC88528T;
KEGG	D04820;
ChEBI	CHEBI:70735 ;
ChEMBL	ChEMBL1237021;
ECHA InfoCard	100.225.187
Chemical and physical data
Formula	C28H36N4O2S
Molar mass	492.68 g·mol−1
3D model (JSmol)	Interactive image;
Specific rotation	[α]20D −59°
Melting point	176 to 178 °C (349 to 352 °F)
Solubility in water	0.224
	SMILES C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O;
	InChI InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1; Key:PQXKDMSYBGKCJA-CVTJIBDQSA-N;

Lurasidone, sold under the brand name Latuda among others, is an antipsychotic medication used to treat schizophrenia and bipolar disorder.^[2] It is taken by mouth.

Common side effects include sleepiness, movement disorders, nausea, and diarrhea.^[2] Serious side effects are valid for all atypical antipsychotics and may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, an increased risk of suicide, angioedema, and high blood sugar levels,^[10] although lurasidone is less likely to cause high blood sugar levels in most patients, hyperosmolar hyperglycemic syndrome may occur.^[2]^[11]^[12] In older people with psychosis as a result of dementia, it may increase the risk of dying.^[2] Use during pregnancy is of unclear safety.^[13]^[14]

Lurasidone was first approved for medical use in the United States in 2010.^[2] In 2013, it was approved in Canada, and by the United States Food and Drug Administration, to treat bipolar depression, either as monotherapy or adjunctively with lithium or valproate.^[15]^[16] Generic versions were approved in the United States in 2019, and became available in 2023.^[17]^[18] In 2021, it was the 193rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.^[19]^[20]

^ "Lurasidone (Latuda) Use During Pregnancy". Drugs.com. 5 February 2020. Archived from the original on 15 October 2020. Retrieved 12 May 2020.
^ ^a ^b ^c ^d ^e ^f "Lurasidone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 21 March 2019. Retrieved 21 March 2019.
^ ^a ^b ^c ^d ^e "Product information Latuda (lurasidone hydrochloride)" (PDF). TGA eBusiness Services. Therapeutic Goods Administration. 28 October 2022. Archived from the original on 28 October 2022. Retrieved 28 October 2022.
^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
^ "Latuda 18.5mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2019. Archived from the original on 14 October 2020. Retrieved 12 May 2020.
^ "Latuda- lurasidone hydrochloride tablet, film coated". DailyMed. Archived from the original on 28 August 2021. Retrieved 12 May 2020.
^ Cite error: The named reference Latuda EPAR was invoked but never defined (see the help page).
^ ^a ^b ^c Cite error: The named reference EMA was invoked but never defined (see the help page).
^ "IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA". Latuda. Archived from the original on 3 December 2022. Retrieved 3 December 2022.
^ Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, et al. (November 2017). "The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis". BMC Psychiatry. 17 (1): 373. doi:10.1186/s12888-017-1539-0. PMC 5698995. PMID 29162032.
^ Hanyu S, Kojima Y, Murai T, Kawashima H (September 2022). "Lurasidone-induced hyperosmolar hyperglycemic syndrome: A case report". Neuropsychopharmacology Reports. 42 (3): 377–379. doi:10.1002/npr2.12259. PMC 9515717. PMID 35609885.
^ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 393–394. ISBN 978-0-85711-338-2.
^ "Lurasidone (Latuda) tablets for the treatment of schizophrenia in adults" (PDF). Archived from the original (PDF) on 27 February 2021. Retrieved 30 April 2020.
^ Bawa R, Scarff JR (2015). "Lurasidone: a new treatment option for bipolar depression-a review". Innovations in Clinical Neuroscience. 12 (1–2): 21–23. PMC 4382136. PMID 25852975.
^ Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A (December 2017). "Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment". International Journal of Bipolar Disorders. 5 (1): 9. doi:10.1186/s40345-017-0075-7. PMC 5332323. PMID 28168632.
^ "Generic Latuda Availability". Drugs.com. Archived from the original on 14 August 2020. Retrieved 30 April 2020.
^ Cite error: The named reference WSJ2019 was invoked but never defined (see the help page).
^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^ "Lurasidone - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

[Drugs.com_pregnancy-1] "Lurasidone (Latuda) Use During Pregnancy". Drugs.com. 5 February 2020. Archived from the original on 15 October 2020. Retrieved 12 May 2020.

[AHFS2019-2] ^ ^a ^b ^c ^d ^e ^f "Lurasidone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 21 March 2019. Retrieved 21 March 2019.

[TGA-3] "Product information Latuda (lurasidone hydrochloride)" (PDF). TGA eBusiness Services. Therapeutic Goods Administration. 28 October 2022. Archived from the original on 28 October 2022. Retrieved 28 October 2022.

[4] "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.

[5] Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

[6] "Latuda 18.5mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2019. Archived from the original on 14 October 2020. Retrieved 12 May 2020.

[Latuda_label-7] "Latuda- lurasidone hydrochloride tablet, film coated". DailyMed. Archived from the original on 28 August 2021. Retrieved 12 May 2020.

[Latuda_EPAR-8] Cite error: The named reference Latuda EPAR was invoked but never defined (see the help page).

[EMA-9] Cite error: The named reference EMA was invoked but never defined (see the help page).

[10] "IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA". Latuda. Archived from the original on 3 December 2022. Retrieved 3 December 2022.

[11] Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, et al. (November 2017). "The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis". BMC Psychiatry. 17 (1): 373. doi:10.1186/s12888-017-1539-0. PMC 5698995. PMID 29162032.

[12] Hanyu S, Kojima Y, Murai T, Kawashima H (September 2022). "Lurasidone-induced hyperosmolar hyperglycemic syndrome: A case report". Neuropsychopharmacology Reports. 42 (3): 377–379. doi:10.1002/npr2.12259. PMC 9515717. PMID 35609885.

[BNF76-13] British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 393–394. ISBN 978-0-85711-338-2.

[14] "Lurasidone (Latuda) tablets for the treatment of schizophrenia in adults" (PDF). Archived from the original (PDF) on 27 February 2021. Retrieved 30 April 2020.

[15] Bawa R, Scarff JR (2015). "Lurasidone: a new treatment option for bipolar depression-a review". Innovations in Clinical Neuroscience. 12 (1–2): 21–23. PMC 4382136. PMID 25852975.

[16] Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A (December 2017). "Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment". International Journal of Bipolar Disorders. 5 (1): 9. doi:10.1186/s40345-017-0075-7. PMC 5332323. PMID 28168632.

[Generic2019-17] "Generic Latuda Availability". Drugs.com. Archived from the original on 14 August 2020. Retrieved 30 April 2020.

[WSJ2019-18] Cite error: The named reference WSJ2019 was invoked but never defined (see the help page).

[19] "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.

[20] "Lurasidone - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

Lurasidone information

and 25 Related for: Lurasidone information

Lurasidone

List of adverse effects of lurasidone

Extrapyramidal symptoms

Atypical antipsychotic

List of antidepressants

Rilmenidine

Somnolence

Antipsychotic

List of psychiatric medications

Oculogyric crisis

Akathisia

Cycloserine

List of psychotropic medications

MDMA

Mood stabilizer

Hydroxyzine

Brazilian Controlled Drugs and Substances Act

Promethazine

Monoamine oxidase inhibitor

Psilocybin

Aripiprazole

Ketamine

Quetiapine

Asenapine

Itraconazole